Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 3/20 | 0.31 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399225 | 0.98 | EPHX2 (0.34) | GABRA1GABRG2GABRB3CNR1CNR2 | |
| SCHEMBL3395246 | 0.89 | CNR1 (0.36) | CNR1CNR2NOS1NOS2 | |
| SCHEMBL19119094 | 0.88 | GABRA1 (0.32) | GABRA1GABRG2GABRB3CNR1CNR2 | |
| SCHEMBL1499472 | 0.87 | CNR1 (0.38) | CNR1CNR2NOS3NOS1NOS2 | |
| SCHEMBL3424937 | 0.85 | CNR1 (0.39) | CNR1CNR2NOS1NOS2 | |
| SCHEMBL3400188 | 0.84 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL3428803 | 0.83 | NOS3 (0.31) | CNR1CNR2NOS3NOS1NOS2 | |
| SCHEMBL3396579 | 0.82 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL4539596 | 0.82 | CNR1 (0.32) | CNR1CNR2NOS3NOS1NOS2 | |
| SCHEMBL3424791 | 0.80 | CNR1 (0.33) | CNR1CNR2EPHX2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245123-B1 | METHODS FOR PRODUCING ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS | CHEMTURA CORP (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8563489-B2 | Alkylated 1,3-benzenediamine compounds and methods for producing same | CHEMTURA CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2245123-A2 | ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | Chemtura Corporation (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009076091-A2 | ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | CHEMTURA CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | LANXESS SOLUTIONS US INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | BBOX1, ABHD5, BRD1 | GABRA1 2052/4885GABRG2 1864/4885GABRB3 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.